The World Health Organization identified antimicrobial resistance (AMR) as one of the greatest threats to human health. Drug-resistant infections already kill hundreds of thousands a year globally, and by 2050 that figure could be more than 10 million (amr.review.org). Of particular concern is the mounting prevalence of infections caused by multidrug resistant (MDR) Gramnegative bacteria. Although Escherichia coli is the most common cause of invasive Gramnegative infections, the most significant challenge comes from Klebsiella pneumoniae. The percentage of isolates resistant to last generation antibiotics continues to increase worldwide.
In fact, the isolation of Klebsiella strains resistant to "last resort" antimicrobials has significantly narrowed, or in some settings completely removed, the therapeutic options for the treatment of Klebsiella infections. To further complicate this scenario, recent population genomic studies have shown that virulent and MDR resistant clones have access to a diverse mobile pool of virulence and antimicrobial resistance genes of high penetrance 1, 2 hence making possible the emergence of an extremely drug-resistant hypervirulent K. pneumoniae clone capable of causing untreatable infections in healthy individuals. It is then not surprising that MDR K.
pneumoniae has been singled out as an "urgent threat to human health" by several institutions including the UK government, the CDC and the WHO. However, and despite the clinical relevance, there is still scant evidence on K. pneumoniae pathogenesis at the molecular and cellular level. Therefore, the development of new therapeutic strategies requires a better understanding of K. pneumoniae pathophysiology in the context of the complex interactions between bacterial pathogens and their hosts.
In this issue of Virulence, Lee et al 3 pneumoniae, the capsule polysaccharide 6 . Capsule mutants are attenuated in the pneumonia mouse model and in the Galleria mellonella one 6, 7 .The capsule polysaccharide protects Klebsiella against the bactericidal action of complement and antimicrobial peptides 8, 9 , limits the activation of inflammatory responses [10] [11] [12] , and reduces phagocytosis by neutrophils and even amoebas 13, 14 . In this work, Lee et al 3 conclusively demonstrate that high glucose levels, but not high glycerol ones, up regulate the transcription of the cps operon with a concomitant increase in the levels of surface exposed polysaccharide. Further studies are required to decipher the molecular basis of this upregulation. In fact, capsule regulation in Klebsiella is still poorly understood. As anticipated, glucose-induced high capsule levels were associated with a further increased in Klebsiella resistance to neutrophils phagocytosis and whole blood leukocyte killing. Since previous studies have shown that there is a correlation between the capsule levels and the resistance to antimicrobial peptides and the induction of inflammatory responses [15] [16] [17] , it is tempting to postulate that poor glycemic control enhances capsuledependent Klebsiella anti-immune mechanisms and, therefore, the virulence of the pathogen.
However sounded this hypothesis, further studies are warranted to provide a global view of Klebsiella transcriptome when grown in high glucose to investigate, for example, whether the expressions of other known Klebsiella virulence factors such as the siderophores, the lipopolysaccharide and the OmpA outer membrane protein are also affected 12, 16, [18] [19] [20] [21] [22] .
Nevertheless, the time is ripe to carry out these studies in vivo using well established obesity or diabetes mellitus animal models thereby allowing a better understanding of Klebsiella biology in the context of the host. This fundamental knowledge is absolutely essential not only to inform the management of diabetic patients but also to develop new therapeutics based on new targets and approaches.
In conclusion, this study by Lee et al establishes that type 2 diabetes mellitus with poor glycemic control is a risk factor for Klebsiella disseminated infections. The reported in vitro data indicates that high glucose may enhance capsule-dependent evasion of the immune system hence contributing to develop disseminated infections. Taken together, this means that therapeutics targeting Klebsiella capsule, or interfering with capsule-mediated antiimmune mechanisms, may be a potential strategy to fight Klebsiella infections.
